Correlation between chemotherapeutic efficacy of paclitaxel and class Ⅲ β-tubulin protein expression in gastric carcinoma patients
10.3760/cma.j.issn.1006-9801.2013.02.007
- VernacularTitle:胃癌患者应用紫杉醇类药物的疗效与β-微管蛋白-Ⅲ表达的相关性
- Author:
Quanliang YANG
;
Dongxiang ZENG
;
Yongping LIU
;
Yang LING
;
Huawei JIANG
;
Jian MA
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Class Ⅲ β-tubulin;
Paclitaxel
- From:
Cancer Research and Clinic
2013;(2):94-95,99
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive value of class Ⅲ β-tubulin protein expression in tumor tissue for the efficacy of taxol combined chemotherapy in stage Ⅲ s/Ⅳ gastric carcinoma patients.Methods Tumor biopsy samples were obtained and class Ⅲ β-tubulin protein expression were examined by immunohistochemical staining before chemotherapy.According to different expression of class Ⅲ β-tubulin,the patients were divided into two groups,group A(low expression of class Ⅲ β-tubulin),group B(high expression of class Ⅲ β-tubulin).The patients were assigned to be received 4 to 6 cycles of Taxol and S-1 chemotherapy regimens and followed up until death or lost.Response rate(RR),overall survival(OS)and time to tumor progression(TTP)were assessed.Results There was no significant difference in clinical characteristics among patients with different expression rate.The RR was higher and TIP was longer in group A than in group B(53.3 ％ vs 36.7 ％,198 days vs 146 days,P ＜ 0.05 respectively),and no significant differences of OS in two groups(P ＞ 0.05).Conclusion The expression level of class Ⅲ β-tubulin in tumor tissue is probably a predictor for the efficacy of taxol in gastric cancer patients,taxol combined chemotherapy is more suitable for patients with lower expression of class Ⅲ β-tubulin.
